Cancer is the second leading cause of death worldwide according to the latest Cancer Report by WHO. Multiple routes involving different proteins that control the development of cancer. Tyrosine receptor kinases play an important role in a variety of cellular processes including growth, motility, differentiation, and metabolism. Tyrosine Kinase Inhibitors prevent and hamper the pathways by targeting signaling molecules that are necessary for cell survival. Docking studies are proved to be an essential tool that facilitates the structural diversity of natural products to be harnessed in an organized manner. In this study, we docked ten Tyrosine Kinase inhibitors with PDB ID: 5JFX to identify the potent inhibitor against the enzyme. The predictive binding of several forms of indazole compounds to Tyrosine Receptor Kinase inhibitor was analysed using docking analysis in an in silico model. Among the compounds, TRK-3 and TRK- 9 with significant docking scores may produce significant anti-breast cancer activity and further in-vitro and in-vivo investigations may prove their therapeutic potential. The study was validated by docking of standard drug Entrectinib. The goal of this work is to use docking and molecular dynamic analysis to investigate the activity of Indazole derivate compounds in inhibiting TRK expression, which plays a key role in cancer cell progression.